数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jose E. Almeida Chair, President and Chief Executive Officer 62 1358.82万美元 44.15 2024-02-08
Stephen N. Oesterle Director 73 35.37万美元 2.18 2024-02-08
Patricia B. Morrison Director 64 31.90万美元 1.53 2024-02-08
Cathy R. Smith Director 60 33.80万美元 1.65 2024-02-08
David S. Wilkes Director 67 30.65万美元 0.28 2024-02-08
Brent Shafer Director 66 26.24万美元 未持股 2024-02-08
William Ampofo II Director -- 未披露 0.39 2024-02-08
Amy A. Wendell Director 62 33.10万美元 1.79 2024-02-08
Peter M. Wilver Director 64 25.24万美元 0.73 2024-02-08
Nancy M. Schlichting Director 70 32.99万美元 0.08 2024-02-08
Stephen H. Rusckowski Director 66 未披露 0.31 2024-02-08

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jose E. Almeida Chair, President and Chief Executive Officer 62 1358.82万美元 44.15 2024-02-08
Joel T. Grade Executive Vice President and Chief Financial Officer 54 未披露 5.37 2024-02-08
Christopher A. Toth Executive Vice President and Group President, Kidney Care 45 未披露 10.87 2024-02-08
Brian C. Stevens Senior Vice President, Chief Accounting Officer and Controller 50 未披露 5.45 2024-02-08
James Borzi Executive Vice President and Chief Supply Chain Officer 61 未披露 未持股 2024-02-08
David S. Rosenbloom Executive Vice President and General Counsel 64 556.03万美元 未持股 2024-02-08
Heather Knight Executive Vice President and Group President, Medical Products & Therapies 52 未披露 5.66 2024-02-08
Reazur Rasul Executive Vice President and Group President, Healthcare Systems & Technologies 47 未披露 未持股 2024-02-08
Alok Sonig Executive Vice President and Group President, Pharmaceuticals 51 未披露 3.19 2024-02-08
Jeanne K. Mason Executive Vice President and Chief Human Resources Officer 68 414.36万美元 未持股 2024-02-08

董事简历

中英对照 |  中文 |  英文
Jose E. Almeida

Jose E. Almeida,自2016年1月起担任董事长、总裁兼首席执行官。他于2015年10月开始担任Baxter的执行官。2015年5月至2015年10月,他在The Carlyle Group担任高级顾问。在此之前,他曾于2012年3月至2015年1月在Medtronic plc(Medtronic)收购Covidien之前担任全球保健产品公司Covidien plc(Covidien)的董事长、总裁兼首席执行官,并于2011年7月至2012年3月担任Covidien总裁兼首席执行官。Almeida先生于2004年4月至2011年6月期间在Covidien(原Tyco Healthcare(Tyco))担任其他行政职务。Almeida先生目前在美国银行董事会任职。他曾担任Ortho-Clinical Diagnostics,Walgreens Boots Alliance,Inc.董事会成员和Partners in Health董事会成员。他还曾担任先进医疗技术协会(AdvaMed)的董事和董事会主席。


Jose E. Almeida,is Chair, President and Chief Executive Officer, having served in that capacity since January 2016. He began serving as an executive officer of Baxter in October 2015. He served as Senior Advisor with The Carlyle Group from May 2015 until October 2015. Previously, he served as the Chairman, President and Chief Executive Officer of Covidien plc (Covidien), a global health care products company, from March 2012 to January 2015, prior to the acquisition of Covidien by Medtronic plc (Medtronic), and President and Chief Executive Officer of Covidien from July 2011 to March 2012. Mr. Almeida served in other executive roles with Covidien (formerly Tyco Healthcare (Tyco)) between April 2004 and June 2011. Mr. Almeida currently serves on the Board of Directors of Bank of America. He previously served as a member of the Board of Directors of Ortho-Clinical Diagnostics, Walgreens Boots Alliance, Inc., and the board of trustees of Partners in Health.
Jose E. Almeida,自2016年1月起担任董事长、总裁兼首席执行官。他于2015年10月开始担任Baxter的执行官。2015年5月至2015年10月,他在The Carlyle Group担任高级顾问。在此之前,他曾于2012年3月至2015年1月在Medtronic plc(Medtronic)收购Covidien之前担任全球保健产品公司Covidien plc(Covidien)的董事长、总裁兼首席执行官,并于2011年7月至2012年3月担任Covidien总裁兼首席执行官。Almeida先生于2004年4月至2011年6月期间在Covidien(原Tyco Healthcare(Tyco))担任其他行政职务。Almeida先生目前在美国银行董事会任职。他曾担任Ortho-Clinical Diagnostics,Walgreens Boots Alliance,Inc.董事会成员和Partners in Health董事会成员。他还曾担任先进医疗技术协会(AdvaMed)的董事和董事会主席。
Jose E. Almeida,is Chair, President and Chief Executive Officer, having served in that capacity since January 2016. He began serving as an executive officer of Baxter in October 2015. He served as Senior Advisor with The Carlyle Group from May 2015 until October 2015. Previously, he served as the Chairman, President and Chief Executive Officer of Covidien plc (Covidien), a global health care products company, from March 2012 to January 2015, prior to the acquisition of Covidien by Medtronic plc (Medtronic), and President and Chief Executive Officer of Covidien from July 2011 to March 2012. Mr. Almeida served in other executive roles with Covidien (formerly Tyco Healthcare (Tyco)) between April 2004 and June 2011. Mr. Almeida currently serves on the Board of Directors of Bank of America. He previously served as a member of the Board of Directors of Ortho-Clinical Diagnostics, Walgreens Boots Alliance, Inc., and the board of trustees of Partners in Health.
Stephen N. Oesterle

Stephen N. Oesterle,是顾问,为医疗保健行业的私人股本和运营公司提供咨询服务。2002年至2015年,他曾担任Medtronic公司的执行委员会的成员,以及高级副总裁,负责医学和技术。此前,他曾担任Massachusetts General Hospital(1998年至2002年)、Stanford University Medical Center (1992年至1998年) 、Georgetown University Medical Center (1991年至1992年)的医学助理教授、侵入性心脏科服务主管。他曾担任HeartWare International, Inc. (HeartWare)的董事(2016年1月至2016年11月),随后Medtronic公司收购HeartWare。


Stephen N. Oesterle,is a consultant, advising private equity and operating companies in the healthcare industry. From 2002 to 2015, he served as a member of the Executive Committee of Medtronic, a global medical technology, services and solutions company, and as Medtronic's Senior Vice President, Medicine and Technology. Previously, he served as an Associate Professor of Medicine and Director of Invasive Cardiology Services at each of Massachusetts General Hospital (1998 to 2002), Stanford University Medical Center (1992 to 1998) and Georgetown University Medical Center (1991 to 1992). Dr. Oesterle currently serves as a director of Paragon 28, Peijia Medical Ltd. and Sigilon Therapeutics, Inc. He previously served as a director of Montes Archimedes Acquisition Corp. (prior to its merger with Roivant Sciences), and REVA Medical, Inc. (REVA).
Stephen N. Oesterle,是顾问,为医疗保健行业的私人股本和运营公司提供咨询服务。2002年至2015年,他曾担任Medtronic公司的执行委员会的成员,以及高级副总裁,负责医学和技术。此前,他曾担任Massachusetts General Hospital(1998年至2002年)、Stanford University Medical Center (1992年至1998年) 、Georgetown University Medical Center (1991年至1992年)的医学助理教授、侵入性心脏科服务主管。他曾担任HeartWare International, Inc. (HeartWare)的董事(2016年1月至2016年11月),随后Medtronic公司收购HeartWare。
Stephen N. Oesterle,is a consultant, advising private equity and operating companies in the healthcare industry. From 2002 to 2015, he served as a member of the Executive Committee of Medtronic, a global medical technology, services and solutions company, and as Medtronic's Senior Vice President, Medicine and Technology. Previously, he served as an Associate Professor of Medicine and Director of Invasive Cardiology Services at each of Massachusetts General Hospital (1998 to 2002), Stanford University Medical Center (1992 to 1998) and Georgetown University Medical Center (1991 to 1992). Dr. Oesterle currently serves as a director of Paragon 28, Peijia Medical Ltd. and Sigilon Therapeutics, Inc. He previously served as a director of Montes Archimedes Acquisition Corp. (prior to its merger with Roivant Sciences), and REVA Medical, Inc. (REVA).
Patricia B. Morrison

Patricia B. Morrison女士,2009年至2018年,Morrison女士担任全球综合医疗服务和产品公司Cardinal Health Inc.的执行副总裁、客户支持服务和首席信息官。在Cardinal,她领导全球信息技术(IT)业务,包括多个业务部门的转型、收购集成和数字战略。在Cardinal之前,Morrison女士于2008年至2009年是技术咨询公司Maintay Partners的首席执行官。她曾担任摩托罗拉公司和办公仓库公司首席信息官,并在通用电气公司、百事可乐、宝洁公司和贵格燕麦公司担任高级IT职位。她目前担任Splunk Inc.董事,她以前曾担任Aramark公司和Virtusa公司的董事。墨里森女士在俄亥俄牛津迈阿密大学拥有学士学位和学士学位。


Patricia B. Morrison,has served as a member of Splunk Inc. Board since 2013. Ms. Morrison was Executive Vice President, Customer Support Services and Chief Information Officer at Cardinal Health, Inc., a provider of healthcare services, from 2009 to 2018. Prior to joining Cardinal Health, Ms. Morrison was Chief Executive Officer of Mainstay Partners, a technology advisory firm, from 2008 to 2009, and Executive Vice President and Chief Information Officer at Motorola, Inc., a designer, manufacturer, marketer and seller of mobility products, from 2005 to 2008. Her previous experience also includes Chief Information Officer of Office Depot, Inc. and senior-level information technology positions at PepsiCo, Inc., The Quaker Oats Company, General Electric Company and The Procter & Gamble Company. Ms. Morrison has served as a member of the board of directors of Baxter International Inc., a global medical products company, since 2019. Ms. Morrison previously served as a member of the board of directors of Aramark, a global provider of food, facilities and uniform services, from 2017 to 2019, and Virtusa Corporation, a global provider of digital strategy, digital engineering, and IT services and solutions, from 2020 to 2021. Ms. Morrison holds a B.A. and B.S. from Miami University in Oxford, Ohio.
Patricia B. Morrison女士,2009年至2018年,Morrison女士担任全球综合医疗服务和产品公司Cardinal Health Inc.的执行副总裁、客户支持服务和首席信息官。在Cardinal,她领导全球信息技术(IT)业务,包括多个业务部门的转型、收购集成和数字战略。在Cardinal之前,Morrison女士于2008年至2009年是技术咨询公司Maintay Partners的首席执行官。她曾担任摩托罗拉公司和办公仓库公司首席信息官,并在通用电气公司、百事可乐、宝洁公司和贵格燕麦公司担任高级IT职位。她目前担任Splunk Inc.董事,她以前曾担任Aramark公司和Virtusa公司的董事。墨里森女士在俄亥俄牛津迈阿密大学拥有学士学位和学士学位。
Patricia B. Morrison,has served as a member of Splunk Inc. Board since 2013. Ms. Morrison was Executive Vice President, Customer Support Services and Chief Information Officer at Cardinal Health, Inc., a provider of healthcare services, from 2009 to 2018. Prior to joining Cardinal Health, Ms. Morrison was Chief Executive Officer of Mainstay Partners, a technology advisory firm, from 2008 to 2009, and Executive Vice President and Chief Information Officer at Motorola, Inc., a designer, manufacturer, marketer and seller of mobility products, from 2005 to 2008. Her previous experience also includes Chief Information Officer of Office Depot, Inc. and senior-level information technology positions at PepsiCo, Inc., The Quaker Oats Company, General Electric Company and The Procter & Gamble Company. Ms. Morrison has served as a member of the board of directors of Baxter International Inc., a global medical products company, since 2019. Ms. Morrison previously served as a member of the board of directors of Aramark, a global provider of food, facilities and uniform services, from 2017 to 2019, and Virtusa Corporation, a global provider of digital strategy, digital engineering, and IT services and solutions, from 2020 to 2021. Ms. Morrison holds a B.A. and B.S. from Miami University in Oxford, Ohio.
Cathy R. Smith

Cathy R. Smith自2020年1月起担任Bright Health的首席行政和财务官,Bright Health是一家以消费者为中心的多元化医疗保健公司。在此之前,Smith女士于2015年9月至2019年11月担任零售商Target Corporation Target的执行副总裁兼首席财务官。在2015年加入Target之前,Smith女士曾于2014年至2015年担任Express Scripts控股公司(Express Scripts)的执行副总裁兼首席财务官,Express Scripts是一家独立的药房福利管理公司;2010年至2014年,Smith女士曾任折扣零售商Walmart Stores Inc.旗下的沃尔玛国际公司(Walmart International)的执行副总裁兼首席财务官。在她的职业生涯早期,她曾在GameStop和其他公司担任首席财务官。Smith女士目前担任PPG工业公司董事。


Cathy R. Smith,has served as Chief Financial and Administrative Officer of Bright Health, a diversified consumer-focused healthcare company, since January 2020. Prior to that, Ms. Smith was Executive Vice President and Chief Financial Officer at Target Corporation (Target), from September 2015 to November 2019. Prior to joining Target in 2015, Ms. Smith served as Executive Vice President and Chief Financial Officer at Express Scripts Holding Company (Express Scripts), an independent pharmacy benefits management company, from 2014 to 2015 and at Walmart International (Walmart), a division of Walmart Stores Inc., from 2010 to 2014. Earlier in her career, she served as Chief Financial Officer at GameStop. Ms. Smith currently serves as director of PPG Industries, Inc.
Cathy R. Smith自2020年1月起担任Bright Health的首席行政和财务官,Bright Health是一家以消费者为中心的多元化医疗保健公司。在此之前,Smith女士于2015年9月至2019年11月担任零售商Target Corporation Target的执行副总裁兼首席财务官。在2015年加入Target之前,Smith女士曾于2014年至2015年担任Express Scripts控股公司(Express Scripts)的执行副总裁兼首席财务官,Express Scripts是一家独立的药房福利管理公司;2010年至2014年,Smith女士曾任折扣零售商Walmart Stores Inc.旗下的沃尔玛国际公司(Walmart International)的执行副总裁兼首席财务官。在她的职业生涯早期,她曾在GameStop和其他公司担任首席财务官。Smith女士目前担任PPG工业公司董事。
Cathy R. Smith,has served as Chief Financial and Administrative Officer of Bright Health, a diversified consumer-focused healthcare company, since January 2020. Prior to that, Ms. Smith was Executive Vice President and Chief Financial Officer at Target Corporation (Target), from September 2015 to November 2019. Prior to joining Target in 2015, Ms. Smith served as Executive Vice President and Chief Financial Officer at Express Scripts Holding Company (Express Scripts), an independent pharmacy benefits management company, from 2014 to 2015 and at Walmart International (Walmart), a division of Walmart Stores Inc., from 2010 to 2014. Earlier in her career, she served as Chief Financial Officer at GameStop. Ms. Smith currently serves as director of PPG Industries, Inc.
David S. Wilkes

David S. Wilkes自2015年起担任弗吉尼亚大学医学院院长。他曾在印第安纳大学医学院担任越来越负责任的职位,最近担任研究事务执行副主任,并在2009年至2015年间担任August M. Watanabe医学研究教授。Wilkes博士是ImmunewWorks公司的联合创始人。ImmunewWorks是一家生物技术初创公司,自2005年起担任首席科学官。自2006年以来,他一直担任Robert Wood Johnson基金会Harold Amos医学院发展项目的国家主任。这个项目旨在增加在美国主要医学院校中代表性不足的少数民族医生科学家。Wilkes博士是一名退伍军人,曾在美国空军医疗队担任三年少校。2020年,他被选入国家医学院。


David S. Wilkes,served as dean of the University of Virginia School of Medicine from 2015 to 2021 and currently serves as dean emeritus. He previously served in positions of increasing responsibility at Indiana University School of Medicine, most recently as the Executive Associate Director for Research Affairs and as the August M. Watanabe Professor of Medical Research between 2009 and 2015. Dr. Wilkes is the co-founder of ImmuneWorks Inc. (ImmuneWorks), a biotechnology start-up company, and has served as its Chief Scientific Officer since 2005. Since 2006, he has served as the National Director of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. This program seeks to increase underrepresented minority physician-scientists at leading medical schools in the United States. Dr. Wilkes is a military veteran, having served three years as a major in the U.S. Air Force Medical Corps. In 2020, he was elected to the National Academy of Medicine. Dr. Wilkes currently serves as a director of Syneos Health.
David S. Wilkes自2015年起担任弗吉尼亚大学医学院院长。他曾在印第安纳大学医学院担任越来越负责任的职位,最近担任研究事务执行副主任,并在2009年至2015年间担任August M. Watanabe医学研究教授。Wilkes博士是ImmunewWorks公司的联合创始人。ImmunewWorks是一家生物技术初创公司,自2005年起担任首席科学官。自2006年以来,他一直担任Robert Wood Johnson基金会Harold Amos医学院发展项目的国家主任。这个项目旨在增加在美国主要医学院校中代表性不足的少数民族医生科学家。Wilkes博士是一名退伍军人,曾在美国空军医疗队担任三年少校。2020年,他被选入国家医学院。
David S. Wilkes,served as dean of the University of Virginia School of Medicine from 2015 to 2021 and currently serves as dean emeritus. He previously served in positions of increasing responsibility at Indiana University School of Medicine, most recently as the Executive Associate Director for Research Affairs and as the August M. Watanabe Professor of Medical Research between 2009 and 2015. Dr. Wilkes is the co-founder of ImmuneWorks Inc. (ImmuneWorks), a biotechnology start-up company, and has served as its Chief Scientific Officer since 2005. Since 2006, he has served as the National Director of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. This program seeks to increase underrepresented minority physician-scientists at leading medical schools in the United States. Dr. Wilkes is a military veteran, having served three years as a major in the U.S. Air Force Medical Corps. In 2020, he was elected to the National Academy of Medicine. Dr. Wilkes currently serves as a director of Syneos Health.
Brent Shafer

Brent Shafer,他是Cerner的前董事长兼首席执行官,Cerner是各种健康信息技术的领先提供商,从医疗设备到电子健康记录到硬件,从2018年到2021年担任该职位。他将于2023年4月28日起担任首席独立董事。加入Cerner之前,他在Koninklijke Philips NV (Philips)担任多个职位,这是一家健康技术公司,专注于改善人们的健康,从健康生活和预防,到诊断、治疗和家庭护理,包括Philips北美的首席执行官,这是诊断成像、图像引导治疗、患者监测和健康信息以及消费者健康和家庭护理的领导者。他也是飞利浦家庭医疗保健解决方案(飞利浦)业务的首席执行官。在加入Philips之前,他曾担任Hillrom's患者护理环境部门的副总裁兼总经理,并在GE医疗系统公司工作,在那里他担任销售、营销和综合管理的关键职位。他还曾担任Hewlett Packard's Medical Products Group和Johnson & Johnson的高级职位。他目前担任触觉系统技术的董事。


Brent Shafer,is the former Chairman and Chief Executive Officer of Cerner, a leading provider of various health information technologies, ranging from medical devices to electronic health records to hardware, serving in this role from 2018 to 2021. He will become the Lead Independent Director effective April 28, 2023. Prior to Cerner, Mr. Shafer held a number of roles at Koninklijke Philips NV (Philips), a health technology company focused on improving people's health across the health continuum from healthy living and prevention, to diagnosis, treatment, and home care, including Chief Executive Officer of Philips North America, a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Mr. Shafer was also the Chief Executive Officer of Philips Home Healthcare Solutions (Philips) business. Before joining Philips, Mr. Shafer was Vice President and General Manager of Hillrom's Patient Care Environment Division and worked at GE Medical Systems where he served in key positions in sales, marketing, and general management. Mr. Shafer has also held senior roles at Hewlett Packard's Medical Products Group and Johnson & Johnson. Mr. Shafer currently services as a director of Tactile Systems Technology.
Brent Shafer,他是Cerner的前董事长兼首席执行官,Cerner是各种健康信息技术的领先提供商,从医疗设备到电子健康记录到硬件,从2018年到2021年担任该职位。他将于2023年4月28日起担任首席独立董事。加入Cerner之前,他在Koninklijke Philips NV (Philips)担任多个职位,这是一家健康技术公司,专注于改善人们的健康,从健康生活和预防,到诊断、治疗和家庭护理,包括Philips北美的首席执行官,这是诊断成像、图像引导治疗、患者监测和健康信息以及消费者健康和家庭护理的领导者。他也是飞利浦家庭医疗保健解决方案(飞利浦)业务的首席执行官。在加入Philips之前,他曾担任Hillrom's患者护理环境部门的副总裁兼总经理,并在GE医疗系统公司工作,在那里他担任销售、营销和综合管理的关键职位。他还曾担任Hewlett Packard's Medical Products Group和Johnson & Johnson的高级职位。他目前担任触觉系统技术的董事。
Brent Shafer,is the former Chairman and Chief Executive Officer of Cerner, a leading provider of various health information technologies, ranging from medical devices to electronic health records to hardware, serving in this role from 2018 to 2021. He will become the Lead Independent Director effective April 28, 2023. Prior to Cerner, Mr. Shafer held a number of roles at Koninklijke Philips NV (Philips), a health technology company focused on improving people's health across the health continuum from healthy living and prevention, to diagnosis, treatment, and home care, including Chief Executive Officer of Philips North America, a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Mr. Shafer was also the Chief Executive Officer of Philips Home Healthcare Solutions (Philips) business. Before joining Philips, Mr. Shafer was Vice President and General Manager of Hillrom's Patient Care Environment Division and worked at GE Medical Systems where he served in key positions in sales, marketing, and general management. Mr. Shafer has also held senior roles at Hewlett Packard's Medical Products Group and Johnson & Johnson. Mr. Shafer currently services as a director of Tactile Systems Technology.
William Ampofo II

William Ampofo II,自2016年以来一直在波音公司工作,目前担任波音全球服务公司的零部件和分销服务业务以及全球服务供应链职能部门的负责人。在此职位上,他领导供应链职能的各个方面,包括在全球70多个国家和300多个地点开展业务的部门。在加入波音公司之前,他在联合技术公司(UTC)工作了22年,担任与财务、信息技术、企业战略和运营相关的职责。他持有Adelphi University的金融学士学位和George Washington University的工商管理硕士学位。他是执行领导委员会的成员,目前担任通用航空制造商协会(General Aviation Manufacturers Association)和达拉斯地区商会(Dallas Regional Chamber)的董事会成员,以及位于康涅狄格州Cheshire的Cheshire Academy的董事会成员。此外,他是霍华德大学供应链管理卓越中心(Center of Excellence In Supply Chain Management)的前顾问委员会成员。


William Ampofo II,has worked for the Boeing Company since 2016 and currently serves as the leader of the Parts & Distribution Services business and the Global Services Supply Chain function for Boeing Global Services. In this capacity, he leads all aspects of the supply chain function, including a division with operations in over 70 countries and more than 300 locations around the world. Prior to joining Boeing, Mr. Ampofo spent 22 years at United Technologies Corporation (UTC) working in roles of increasing responsibility related to finance, information technology, corporate strategy and operations. Mr. Ampofo earned a bachelor's degree in finance from Adelphi University and a Master of Business Administration from George Washington University. He is a member of The Executive Leadership Council and currently serves on the board of directors for the General Aviation Manufacturers Association and the Dallas Regional Chamber as well as the board of trustees for Cheshire Academy in Cheshire, Connecticut. In addition, he is a past advisory board member for Howard University's Center of Excellence in Supply Chain Management.
William Ampofo II,自2016年以来一直在波音公司工作,目前担任波音全球服务公司的零部件和分销服务业务以及全球服务供应链职能部门的负责人。在此职位上,他领导供应链职能的各个方面,包括在全球70多个国家和300多个地点开展业务的部门。在加入波音公司之前,他在联合技术公司(UTC)工作了22年,担任与财务、信息技术、企业战略和运营相关的职责。他持有Adelphi University的金融学士学位和George Washington University的工商管理硕士学位。他是执行领导委员会的成员,目前担任通用航空制造商协会(General Aviation Manufacturers Association)和达拉斯地区商会(Dallas Regional Chamber)的董事会成员,以及位于康涅狄格州Cheshire的Cheshire Academy的董事会成员。此外,他是霍华德大学供应链管理卓越中心(Center of Excellence In Supply Chain Management)的前顾问委员会成员。
William Ampofo II,has worked for the Boeing Company since 2016 and currently serves as the leader of the Parts & Distribution Services business and the Global Services Supply Chain function for Boeing Global Services. In this capacity, he leads all aspects of the supply chain function, including a division with operations in over 70 countries and more than 300 locations around the world. Prior to joining Boeing, Mr. Ampofo spent 22 years at United Technologies Corporation (UTC) working in roles of increasing responsibility related to finance, information technology, corporate strategy and operations. Mr. Ampofo earned a bachelor's degree in finance from Adelphi University and a Master of Business Administration from George Washington University. He is a member of The Executive Leadership Council and currently serves on the board of directors for the General Aviation Manufacturers Association and the Dallas Regional Chamber as well as the board of trustees for Cheshire Academy in Cheshire, Connecticut. In addition, he is a past advisory board member for Howard University's Center of Excellence in Supply Chain Management.
Amy A. Wendell

Amy A. Wendell,将因此次分配而被任命为Solventum Corporation董事会成员。2016年至2019年担任Perella Weinberg合伙人医疗健康投资银行业务高级顾问。从2015年到2018年9月,Wendell女士担任麦肯锡战略和企业融资业务的高级顾问,还担任麦肯锡交易咨询委员会的成员,帮助确定并购趋势,并帮助塑造麦肯锡的知识议程。从1986年到2015年1月,Wendell女士在Covidien plc(包括其前身Tyco Healthcare和Kendall Healthcare Products)担任过越来越多的职务,包括工程、产品管理和业务发展。从2006年12月到2015年1月Covidien被美敦力 PLC收购,她担任战略和业务发展高级副总裁,领导公司的战略和投资组合管理计划,并管理所有业务发展,包括收购、股权投资、资产剥离和许可/分销。Wendell女士担任AxoGen,Inc.的首席董事,担任提名和治理委员会以及审计委员会成员;在百特国际,Inc.的董事会担任质量、合规和技术委员会以及薪酬和人力资本委员会成员;在Hologic, Inc.的董事会担任审计和财务委员会成员。她还担任Por Cristo的董事会成员,Por Cristo是一家非营利慈善医疗服务组织,参与拉丁美洲高危妇女和儿童的医疗保健工作。Wendell女士拥有劳伦斯理工大学机械工程理学学士学位和伊利诺伊大学生物医学工程理学硕士学位。


Amy A. Wendell,will be appointed to Solventum Corporation board of directors in connection with the distribution. She was a Senior Advisor for Perella Weinberg Partner's Healthcare Investment Banking Practice from 2016 to 2019. From 2015 to September 2018, Ms. Wendell served as a Senior Advisor for McKinsey's Strategy and Corporate Finance Practice and also served as a member of McKinsey's Transactions Advisory Board to help define trends in mergers and acquisitions, as well as help shape McKinsey's knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including engineering, product management and business development. From December 2006 until Covidien's acquisition by Medtronic plc in January 2015, she served as Senior Vice President of Strategy and Business Development, where she led the company's strategy and portfolio management initiatives and managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution. Ms. Wendell serves as Lead Director of AxoGen, Inc., where she is a member of the Nominating and Governance Committee and the Audit Committee; on the board of directors of Baxter International, Inc., where she is a member of the Quality, Compliance and Technology Committee and Compensation and Human Capital Committee; and on the board of directors of Hologic, Inc., where she is a member of the Audit and Finance Committee. She also serves on the board of Por Cristo, a non-profit charitable medical service organization involved in health care work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science in mechanical engineering from Lawrence Technological University and a Master of Science degree in biomedical engineering from the University of Illinois.
Amy A. Wendell,将因此次分配而被任命为Solventum Corporation董事会成员。2016年至2019年担任Perella Weinberg合伙人医疗健康投资银行业务高级顾问。从2015年到2018年9月,Wendell女士担任麦肯锡战略和企业融资业务的高级顾问,还担任麦肯锡交易咨询委员会的成员,帮助确定并购趋势,并帮助塑造麦肯锡的知识议程。从1986年到2015年1月,Wendell女士在Covidien plc(包括其前身Tyco Healthcare和Kendall Healthcare Products)担任过越来越多的职务,包括工程、产品管理和业务发展。从2006年12月到2015年1月Covidien被美敦力 PLC收购,她担任战略和业务发展高级副总裁,领导公司的战略和投资组合管理计划,并管理所有业务发展,包括收购、股权投资、资产剥离和许可/分销。Wendell女士担任AxoGen,Inc.的首席董事,担任提名和治理委员会以及审计委员会成员;在百特国际,Inc.的董事会担任质量、合规和技术委员会以及薪酬和人力资本委员会成员;在Hologic, Inc.的董事会担任审计和财务委员会成员。她还担任Por Cristo的董事会成员,Por Cristo是一家非营利慈善医疗服务组织,参与拉丁美洲高危妇女和儿童的医疗保健工作。Wendell女士拥有劳伦斯理工大学机械工程理学学士学位和伊利诺伊大学生物医学工程理学硕士学位。
Amy A. Wendell,will be appointed to Solventum Corporation board of directors in connection with the distribution. She was a Senior Advisor for Perella Weinberg Partner's Healthcare Investment Banking Practice from 2016 to 2019. From 2015 to September 2018, Ms. Wendell served as a Senior Advisor for McKinsey's Strategy and Corporate Finance Practice and also served as a member of McKinsey's Transactions Advisory Board to help define trends in mergers and acquisitions, as well as help shape McKinsey's knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including engineering, product management and business development. From December 2006 until Covidien's acquisition by Medtronic plc in January 2015, she served as Senior Vice President of Strategy and Business Development, where she led the company's strategy and portfolio management initiatives and managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution. Ms. Wendell serves as Lead Director of AxoGen, Inc., where she is a member of the Nominating and Governance Committee and the Audit Committee; on the board of directors of Baxter International, Inc., where she is a member of the Quality, Compliance and Technology Committee and Compensation and Human Capital Committee; and on the board of directors of Hologic, Inc., where she is a member of the Audit and Finance Committee. She also serves on the board of Por Cristo, a non-profit charitable medical service organization involved in health care work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science in mechanical engineering from Lawrence Technological University and a Master of Science degree in biomedical engineering from the University of Illinois.
Peter M. Wilver

Peter M. Wilver, 自2010年加入公司董事。他是赛默飞世尔科技公司(一家公开上市的试验产品和服务领先供应商)高级副总裁和首席财务官。2000年加入赛默飞世尔科技公司(前身热电公司)担任财务运营部副总裁并在2004年被任命为首席财务官。加入赛默飞世尔科技之前,他曾在通用电力、Grimes航空航天公司和霍尼韦尔国际公司(原联信公司)工作,最近的职位包括电子材料业务部副总裁和首席财务官。


Peter M. Wilver joined Evoqua Water Technologies Corp. Board in 2018. Mr. Wilver, a former technology manufacturing and services executive and certified public accountant, served in leadership roles at Thermo Fisher Scientific Inc. ("Thermo Fisher"), a leading provider of laboratory products and services, and its predecessor, Thermo Electron Corp. ("Thermo Electron"), for nearly two decades. At Thermo Fisher, Mr. Wilver served as Executive Vice President and Chief Administrative Officer from 2015 until his retirement in 2017 and as the Chief Financial Officer from 2006 to 2015. Mr. Wilver also served as the Chief Financial Officer of Thermo Electron from 2004 to 2006, after joining that company in 2000. Prior to Thermo Electron, Mr. Wilver worked for General Electric, Grimes Aerospace Company, and Honeywell International (formerly AlliedSignal), where he was Vice President and Chief Financial Officer of the electronic materials business. Mr. Wilver currently serves on the boards of directors of Baxter International Inc., where he is a member of the compensation committee; LivaNova PLC, where he is a member of the audit and compliance and compensation committees; and Shoals Technologies Group, Inc., where he is the chair of the audit committee and a member of the nominating and corporate governance committee. Mr. Wilver previously served on the boards of directors of CIRCOR International, Inc., where he was the chair of the audit committee and a member of the compensation committee; and Tenet Healthcare Corporation, where he was a member of the audit and human resources committees. Mr. Wilver earned a B.S.B.A. in Accounting from The Ohio State University.
Peter M. Wilver, 自2010年加入公司董事。他是赛默飞世尔科技公司(一家公开上市的试验产品和服务领先供应商)高级副总裁和首席财务官。2000年加入赛默飞世尔科技公司(前身热电公司)担任财务运营部副总裁并在2004年被任命为首席财务官。加入赛默飞世尔科技之前,他曾在通用电力、Grimes航空航天公司和霍尼韦尔国际公司(原联信公司)工作,最近的职位包括电子材料业务部副总裁和首席财务官。
Peter M. Wilver joined Evoqua Water Technologies Corp. Board in 2018. Mr. Wilver, a former technology manufacturing and services executive and certified public accountant, served in leadership roles at Thermo Fisher Scientific Inc. ("Thermo Fisher"), a leading provider of laboratory products and services, and its predecessor, Thermo Electron Corp. ("Thermo Electron"), for nearly two decades. At Thermo Fisher, Mr. Wilver served as Executive Vice President and Chief Administrative Officer from 2015 until his retirement in 2017 and as the Chief Financial Officer from 2006 to 2015. Mr. Wilver also served as the Chief Financial Officer of Thermo Electron from 2004 to 2006, after joining that company in 2000. Prior to Thermo Electron, Mr. Wilver worked for General Electric, Grimes Aerospace Company, and Honeywell International (formerly AlliedSignal), where he was Vice President and Chief Financial Officer of the electronic materials business. Mr. Wilver currently serves on the boards of directors of Baxter International Inc., where he is a member of the compensation committee; LivaNova PLC, where he is a member of the audit and compliance and compensation committees; and Shoals Technologies Group, Inc., where he is the chair of the audit committee and a member of the nominating and corporate governance committee. Mr. Wilver previously served on the boards of directors of CIRCOR International, Inc., where he was the chair of the audit committee and a member of the compensation committee; and Tenet Healthcare Corporation, where he was a member of the audit and human resources committees. Mr. Wilver earned a B.S.B.A. in Accounting from The Ohio State University.
Nancy M. Schlichting

Nancy M. Schlichting,2003年6月起担任亨利·福特健康体系CEO。1999年6月至2003年6月,她担任该体系执行副总裁兼首席运营官;2001年8月至2003年6月担任亨利·福特医院总裁兼CEO。她也曾担任底特律商会主席和克雷斯吉基金会董事,担任薪酬委员会主席。


Nancy M. Schlichting,joined the Board following Baxter's acquisition of Hillrom, where she had previously served as a director and Chair of its Compensation and Management Development Committee. Ms. Schlichting is the retired President and Chief Executive Officer of Henry Ford Health System (HFHS) in Detroit, Michigan, a non-profit healthcare organization, serving in this role from June 2003 to January 2017. She joined HFHS in 1998 as Senior Vice President and Chief Administrative Officer and was promoted to Executive Vice President and Chief Operating Officer from 1999 to 2003 and President and Chief Executive Officer of Henry Ford Hospital from 2001 to 2003. She currently serves as a director of Walgreens Boots Alliance and Encompass Health, InStride, Inc., as a trustee of the Kresge Foundation and Duke University and as the vice-chair of the Duke University Health System Board. She previously served as a director of Pear Therapeutics, Inc.
Nancy M. Schlichting,2003年6月起担任亨利·福特健康体系CEO。1999年6月至2003年6月,她担任该体系执行副总裁兼首席运营官;2001年8月至2003年6月担任亨利·福特医院总裁兼CEO。她也曾担任底特律商会主席和克雷斯吉基金会董事,担任薪酬委员会主席。
Nancy M. Schlichting,joined the Board following Baxter's acquisition of Hillrom, where she had previously served as a director and Chair of its Compensation and Management Development Committee. Ms. Schlichting is the retired President and Chief Executive Officer of Henry Ford Health System (HFHS) in Detroit, Michigan, a non-profit healthcare organization, serving in this role from June 2003 to January 2017. She joined HFHS in 1998 as Senior Vice President and Chief Administrative Officer and was promoted to Executive Vice President and Chief Operating Officer from 1999 to 2003 and President and Chief Executive Officer of Henry Ford Hospital from 2001 to 2003. She currently serves as a director of Walgreens Boots Alliance and Encompass Health, InStride, Inc., as a trustee of the Kresge Foundation and Duke University and as the vice-chair of the Duke University Health System Board. She previously served as a director of Pear Therapeutics, Inc.
Stephen H. Rusckowski

Stephen H. Rusckowski,总裁兼首席执行官。在他2012年5月加入本公司之前,自2006年10月以来他担任皇家飞利浦电子最大的单位,飞利浦医疗的首席执行官,和皇家飞利浦电子及其执行委员会,管理委员会的成员。在此之前,他在皇家飞利浦电子公司的成像系统担任首席执行官。在2001年加入飞利浦之前,他在休利特帕卡德/安捷伦科技医疗担任过很多管理工作。他自2012N年5月起担任公司的董事。他拥有伍斯特理工学院机械工程学士学位和麻省理工学院斯隆管理学院管理科学硕士学位。


Stephen H. Rusckowski has been Chief Executive Officer and President of Quest Diagnostics since May 2012 and Chairman of the Board since January 2017. From November 2006 to May 2012 Mr. Rusckowski was the Chief Executive Officer of Philips Healthcare, the largest unit of Royal Philips Electronics, and a member of the Board of Management of Royal Philips Electronics and its Executive Committee. He joined Philips when it acquired Agilent's Healthcare Solutions Group in 2001 and was the CEO of Philips Imaging Systems business group before assuming his role as CEO of Philips Healthcare. Mr. Rusckowski served as the Chairman of the American Clinical Laboratory Association from 2014 to 2017. He was a director of Xerox Corporation from 2015 to 2018 and was a director of Covidien plc from 2013 to 2015. Mr. Rusckowski is also an Emeritus Director of Project HOPE, a global health education and humanitarian assistance organization. He earned a bachelor's degree in mechanical engineering from Worcester Polytechnic Institute and a Master of Management Science from the Massachusetts Institute of Technology's Sloan School of Management.
Stephen H. Rusckowski,总裁兼首席执行官。在他2012年5月加入本公司之前,自2006年10月以来他担任皇家飞利浦电子最大的单位,飞利浦医疗的首席执行官,和皇家飞利浦电子及其执行委员会,管理委员会的成员。在此之前,他在皇家飞利浦电子公司的成像系统担任首席执行官。在2001年加入飞利浦之前,他在休利特帕卡德/安捷伦科技医疗担任过很多管理工作。他自2012N年5月起担任公司的董事。他拥有伍斯特理工学院机械工程学士学位和麻省理工学院斯隆管理学院管理科学硕士学位。
Stephen H. Rusckowski has been Chief Executive Officer and President of Quest Diagnostics since May 2012 and Chairman of the Board since January 2017. From November 2006 to May 2012 Mr. Rusckowski was the Chief Executive Officer of Philips Healthcare, the largest unit of Royal Philips Electronics, and a member of the Board of Management of Royal Philips Electronics and its Executive Committee. He joined Philips when it acquired Agilent's Healthcare Solutions Group in 2001 and was the CEO of Philips Imaging Systems business group before assuming his role as CEO of Philips Healthcare. Mr. Rusckowski served as the Chairman of the American Clinical Laboratory Association from 2014 to 2017. He was a director of Xerox Corporation from 2015 to 2018 and was a director of Covidien plc from 2013 to 2015. Mr. Rusckowski is also an Emeritus Director of Project HOPE, a global health education and humanitarian assistance organization. He earned a bachelor's degree in mechanical engineering from Worcester Polytechnic Institute and a Master of Management Science from the Massachusetts Institute of Technology's Sloan School of Management.

高管简历

中英对照 |  中文 |  英文
Jose E. Almeida

Jose E. Almeida,自2016年1月起担任董事长、总裁兼首席执行官。他于2015年10月开始担任Baxter的执行官。2015年5月至2015年10月,他在The Carlyle Group担任高级顾问。在此之前,他曾于2012年3月至2015年1月在Medtronic plc(Medtronic)收购Covidien之前担任全球保健产品公司Covidien plc(Covidien)的董事长、总裁兼首席执行官,并于2011年7月至2012年3月担任Covidien总裁兼首席执行官。Almeida先生于2004年4月至2011年6月期间在Covidien(原Tyco Healthcare(Tyco))担任其他行政职务。Almeida先生目前在美国银行董事会任职。他曾担任Ortho-Clinical Diagnostics,Walgreens Boots Alliance,Inc.董事会成员和Partners in Health董事会成员。他还曾担任先进医疗技术协会(AdvaMed)的董事和董事会主席。


Jose E. Almeida,is Chair, President and Chief Executive Officer, having served in that capacity since January 2016. He began serving as an executive officer of Baxter in October 2015. He served as Senior Advisor with The Carlyle Group from May 2015 until October 2015. Previously, he served as the Chairman, President and Chief Executive Officer of Covidien plc (Covidien), a global health care products company, from March 2012 to January 2015, prior to the acquisition of Covidien by Medtronic plc (Medtronic), and President and Chief Executive Officer of Covidien from July 2011 to March 2012. Mr. Almeida served in other executive roles with Covidien (formerly Tyco Healthcare (Tyco)) between April 2004 and June 2011. Mr. Almeida currently serves on the Board of Directors of Bank of America. He previously served as a member of the Board of Directors of Ortho-Clinical Diagnostics, Walgreens Boots Alliance, Inc., and the board of trustees of Partners in Health.
Jose E. Almeida,自2016年1月起担任董事长、总裁兼首席执行官。他于2015年10月开始担任Baxter的执行官。2015年5月至2015年10月,他在The Carlyle Group担任高级顾问。在此之前,他曾于2012年3月至2015年1月在Medtronic plc(Medtronic)收购Covidien之前担任全球保健产品公司Covidien plc(Covidien)的董事长、总裁兼首席执行官,并于2011年7月至2012年3月担任Covidien总裁兼首席执行官。Almeida先生于2004年4月至2011年6月期间在Covidien(原Tyco Healthcare(Tyco))担任其他行政职务。Almeida先生目前在美国银行董事会任职。他曾担任Ortho-Clinical Diagnostics,Walgreens Boots Alliance,Inc.董事会成员和Partners in Health董事会成员。他还曾担任先进医疗技术协会(AdvaMed)的董事和董事会主席。
Jose E. Almeida,is Chair, President and Chief Executive Officer, having served in that capacity since January 2016. He began serving as an executive officer of Baxter in October 2015. He served as Senior Advisor with The Carlyle Group from May 2015 until October 2015. Previously, he served as the Chairman, President and Chief Executive Officer of Covidien plc (Covidien), a global health care products company, from March 2012 to January 2015, prior to the acquisition of Covidien by Medtronic plc (Medtronic), and President and Chief Executive Officer of Covidien from July 2011 to March 2012. Mr. Almeida served in other executive roles with Covidien (formerly Tyco Healthcare (Tyco)) between April 2004 and June 2011. Mr. Almeida currently serves on the Board of Directors of Bank of America. He previously served as a member of the Board of Directors of Ortho-Clinical Diagnostics, Walgreens Boots Alliance, Inc., and the board of trustees of Partners in Health.
Joel T. Grade

Joel T. Grade,他曾一直担任Sysco公司的执行副总裁兼首席财务官(2015年9月1日以来),并被提升为高级财务副总裁兼首席会计官(2014年2月以来)。他的职业生涯始于1996年担任Sysco公司的雇员审计师。他于1999年晋升为助理经理,负责运行审核。他于2000年担任Sysco Austin公司的总会计师,于2002年被任命为Sysco Chicago公司的财务副总裁兼首席财务官,并于2007年成为Sysco Canada公司的财务副总裁兼首席财务官。他于2010年晋升为Sysco Corporate的餐饮业务副总裁,以及Sysco Canada公司的总裁(直到2012年5月被任命为高级副总裁,负责餐饮服务操作)。


Joel T. Grade,is Executive Vice President and Chief Financial Officer. Mr. Grade joined Baxter in 2023 following a 25-year career with Sysco Corporation (Sysco), the world's global foodservice leader. He most recently served as Sysco's Executive Vice President, Corporate Development from 2020 to 2023. His previous roles at Sysco included Executive Vice President and Chief Financial Officer from 2015 to 2020, Senior Vice President of Finance and Chief Accounting Officer, and Senior Vice President of foodservice operations. He currently serves as a member of Northwestern University-Kellogg School of Business Financial Network Advisory Board and the Dean's External Advisory Board of the University of Wisconsin School of Business.
Joel T. Grade,他曾一直担任Sysco公司的执行副总裁兼首席财务官(2015年9月1日以来),并被提升为高级财务副总裁兼首席会计官(2014年2月以来)。他的职业生涯始于1996年担任Sysco公司的雇员审计师。他于1999年晋升为助理经理,负责运行审核。他于2000年担任Sysco Austin公司的总会计师,于2002年被任命为Sysco Chicago公司的财务副总裁兼首席财务官,并于2007年成为Sysco Canada公司的财务副总裁兼首席财务官。他于2010年晋升为Sysco Corporate的餐饮业务副总裁,以及Sysco Canada公司的总裁(直到2012年5月被任命为高级副总裁,负责餐饮服务操作)。
Joel T. Grade,is Executive Vice President and Chief Financial Officer. Mr. Grade joined Baxter in 2023 following a 25-year career with Sysco Corporation (Sysco), the world's global foodservice leader. He most recently served as Sysco's Executive Vice President, Corporate Development from 2020 to 2023. His previous roles at Sysco included Executive Vice President and Chief Financial Officer from 2015 to 2020, Senior Vice President of Finance and Chief Accounting Officer, and Senior Vice President of foodservice operations. He currently serves as a member of Northwestern University-Kellogg School of Business Financial Network Advisory Board and the Dean's External Advisory Board of the University of Wisconsin School of Business.
Christopher A. Toth

Christopher A. Toth自2018年10月起被任命为肿瘤学系统总裁。托斯先生于2001年加入瓦里安(Varian),在其任职期间曾担任多个跨职能职位和执行职务。在被任命为肿瘤系统总裁之前,Toth先生于2017年1月至2018年9月担任全球商业和现场运营总裁,负责肿瘤系统和Proton Solutions的全球销售战略和执行。此外,Toth先生还负责肿瘤学系统业务的全球现场服务,应用培训,市场准入和区域营销。从2014年9月至2017年1月,托斯先生(Toth)担任美洲肿瘤系统总裁,从2011年4月至2014年9月担任全球营销副总裁。托斯先生拥有学士学位俄勒冈大学隆德奎斯特商学院(Lundquist College of Business)获得工商管理学位,主修市场营销。


Christopher A. Toth was appointed President and Chief Operating Officer in October 2020. Mr. Toth served as President of Oncology Systems from October 2018 to October 2020. Mr. Toth joined Varian in 2001 and has held multiple cross-functional roles and executive positions during his tenure with the company. Prior to his appointment as President of Oncology Systems, Mr. Toth served as President of Global Commercial and Field Operations from January 2017 to September 2018 where he was responsible for global sales strategy and execution for Oncology Systems and Proton Solutions. Additionally, in this role, Mr. Toth was responsible for global field service, applications training, market access and regional marketing for the Oncology Systems business. From September 2014 to January 2017 Mr. Toth was President, Oncology Systems Americas and from April 2011 to September 2014 Vice President, Global Marketing. Mr. Toth holds a B.A. degree in Business Administration with a concentration in Marketing from the Lundquist College of Business at the University of Oregon.
Christopher A. Toth自2018年10月起被任命为肿瘤学系统总裁。托斯先生于2001年加入瓦里安(Varian),在其任职期间曾担任多个跨职能职位和执行职务。在被任命为肿瘤系统总裁之前,Toth先生于2017年1月至2018年9月担任全球商业和现场运营总裁,负责肿瘤系统和Proton Solutions的全球销售战略和执行。此外,Toth先生还负责肿瘤学系统业务的全球现场服务,应用培训,市场准入和区域营销。从2014年9月至2017年1月,托斯先生(Toth)担任美洲肿瘤系统总裁,从2011年4月至2014年9月担任全球营销副总裁。托斯先生拥有学士学位俄勒冈大学隆德奎斯特商学院(Lundquist College of Business)获得工商管理学位,主修市场营销。
Christopher A. Toth was appointed President and Chief Operating Officer in October 2020. Mr. Toth served as President of Oncology Systems from October 2018 to October 2020. Mr. Toth joined Varian in 2001 and has held multiple cross-functional roles and executive positions during his tenure with the company. Prior to his appointment as President of Oncology Systems, Mr. Toth served as President of Global Commercial and Field Operations from January 2017 to September 2018 where he was responsible for global sales strategy and execution for Oncology Systems and Proton Solutions. Additionally, in this role, Mr. Toth was responsible for global field service, applications training, market access and regional marketing for the Oncology Systems business. From September 2014 to January 2017 Mr. Toth was President, Oncology Systems Americas and from April 2011 to September 2014 Vice President, Global Marketing. Mr. Toth holds a B.A. degree in Business Administration with a concentration in Marketing from the Lundquist College of Business at the University of Oregon.
Brian C. Stevens

Brian C. Stevens,他于2018年加入百特,担任高级副总裁、首席会计官和财务总监。在加入Baxter之前,他曾任职Groupon, Inc.,最近担任财务主管和首席会计官。在担任财务主管之前,他曾于2012年至2016年担任Groupon的首席会计官。在加入Groupon之前,他在KPMG LLP工作了16年,最近担任审计合伙人。他持有the University of Illinois at Urbana-Champaign的会计理学学士学位,是伊利诺伊州和纽约州的注册会计师。


Brian C. Stevens,joined Baxter in 2018 as Senior Vice President, Chief Accounting Officer and Controller. Before joining Baxter, Mr. Stevens worked for Groupon, Inc., where he most recently served as treasurer and chief accounting officer. He had served as Groupon's chief accounting officer from 2012 to 2016 before assuming the treasurer role. Prior to joining Groupon, Mr. Stevens spent 16 years with KPMG LLP, most recently as an audit partner.Mr. Stevens received his bachelor of science degree in accountancy from the University of Illinois at Urbana-Champaign and is a licensed certified public accountant in Illinois and New York.
Brian C. Stevens,他于2018年加入百特,担任高级副总裁、首席会计官和财务总监。在加入Baxter之前,他曾任职Groupon, Inc.,最近担任财务主管和首席会计官。在担任财务主管之前,他曾于2012年至2016年担任Groupon的首席会计官。在加入Groupon之前,他在KPMG LLP工作了16年,最近担任审计合伙人。他持有the University of Illinois at Urbana-Champaign的会计理学学士学位,是伊利诺伊州和纽约州的注册会计师。
Brian C. Stevens,joined Baxter in 2018 as Senior Vice President, Chief Accounting Officer and Controller. Before joining Baxter, Mr. Stevens worked for Groupon, Inc., where he most recently served as treasurer and chief accounting officer. He had served as Groupon's chief accounting officer from 2012 to 2016 before assuming the treasurer role. Prior to joining Groupon, Mr. Stevens spent 16 years with KPMG LLP, most recently as an audit partner.Mr. Stevens received his bachelor of science degree in accountancy from the University of Illinois at Urbana-Champaign and is a licensed certified public accountant in Illinois and New York.
James Borzi

James Borzi,他于2020年8月从GE Healthcare加入Baxter,并在2019年至2020年间担任副总裁兼首席供应链官。在加入GE Healthcare之前,他曾在Becton Dickinson BD担任过五年的制造运营领导职务;他在BD的最后一个职务是全球运营执行副总裁兼首席供应链官。在其职业生涯早期,他曾任Hydro Aluminum运营与技术高级副总裁和Lennox International全球运营执行副总裁。在此之前,他是AEES的首席运营官和美国铝业负责美洲业务的高级副总裁。


James Borzi,is Executive Vice President and Chief Supply Chain Officer. He joined Baxter in August 2020 from GE Healthcare, where he served as Vice President, Chief Supply Chain Officer from 2019 to 2020. Prior to joining GE Healthcare, he served in various manufacturing operations leadership roles at Becton Dickinson (BD), including Executive Vice President of Global Operations and Chief Supply Chain Officer from 2013 to 2019. Earlier in his career, he was Senior Vice President of Operations & Technology at Hydro Aluminum and Executive Vice President of Worldwide Operations at Lennox International. Prior to that, he was the Chief Operating Officer at AEES Inc. and Senior Vice President of Americas Operations at Alcoa Corporation. Mr. Borzi is a senior advisor to the NAI Group, a Pritzker Private Capital company.
James Borzi,他于2020年8月从GE Healthcare加入Baxter,并在2019年至2020年间担任副总裁兼首席供应链官。在加入GE Healthcare之前,他曾在Becton Dickinson BD担任过五年的制造运营领导职务;他在BD的最后一个职务是全球运营执行副总裁兼首席供应链官。在其职业生涯早期,他曾任Hydro Aluminum运营与技术高级副总裁和Lennox International全球运营执行副总裁。在此之前,他是AEES的首席运营官和美国铝业负责美洲业务的高级副总裁。
James Borzi,is Executive Vice President and Chief Supply Chain Officer. He joined Baxter in August 2020 from GE Healthcare, where he served as Vice President, Chief Supply Chain Officer from 2019 to 2020. Prior to joining GE Healthcare, he served in various manufacturing operations leadership roles at Becton Dickinson (BD), including Executive Vice President of Global Operations and Chief Supply Chain Officer from 2013 to 2019. Earlier in his career, he was Senior Vice President of Operations & Technology at Hydro Aluminum and Executive Vice President of Worldwide Operations at Lennox International. Prior to that, he was the Chief Operating Officer at AEES Inc. and Senior Vice President of Americas Operations at Alcoa Corporation. Mr. Borzi is a senior advisor to the NAI Group, a Pritzker Private Capital company.
David S. Rosenbloom

David S. Rosenbloom是高级副总裁兼总法律顾问。Rosenbloom先生从McDermott Will & Emery(McDermott)加入Baxter,在那里他担任了24年的合伙人,并于2017年至2022年担任诉讼业务组的全球主管。在加入McDermott之前,他曾在美国伊利诺伊州北区检察官办公室任职八年。Rosenbloom先生是消化健康基金会的董事会成员,该基金会支持西北消化健康中心的研究,该中心是西北纪念医院西北医学的一部分。


David S. Rosenbloom,is Executive Vice President and General Counsel. Mr. Rosenbloom joined Baxter from McDermott Will & Emery (McDermott), where he served as a partner for 24 years and Global Head of the Litigation Practice Group from 2017 to 2022. Prior to McDermott, he served for eight years in the U.S. Attorney's Office for the Northern District of Illinois. Mr. Rosenbloom is a member of the Board of the Digestive Health Foundation, which supports research at Northwestern Digestive Health Center, which is part of Northwestern Medicine at Northwestern Memorial Hospital.
David S. Rosenbloom是高级副总裁兼总法律顾问。Rosenbloom先生从McDermott Will & Emery(McDermott)加入Baxter,在那里他担任了24年的合伙人,并于2017年至2022年担任诉讼业务组的全球主管。在加入McDermott之前,他曾在美国伊利诺伊州北区检察官办公室任职八年。Rosenbloom先生是消化健康基金会的董事会成员,该基金会支持西北消化健康中心的研究,该中心是西北纪念医院西北医学的一部分。
David S. Rosenbloom,is Executive Vice President and General Counsel. Mr. Rosenbloom joined Baxter from McDermott Will & Emery (McDermott), where he served as a partner for 24 years and Global Head of the Litigation Practice Group from 2017 to 2022. Prior to McDermott, he served for eight years in the U.S. Attorney's Office for the Northern District of Illinois. Mr. Rosenbloom is a member of the Board of the Digestive Health Foundation, which supports research at Northwestern Digestive Health Center, which is part of Northwestern Medicine at Northwestern Memorial Hospital.
Heather Knight

Heather Knight是医疗产品和疗法执行副总裁兼集团总裁。自2021年起担任拉丁美洲和加拿大急性疗法、临床营养、药物输送、总裁后,她于2023年被任命为领导医疗产品和疗法的职务。她此前曾于2019年至2021年担任美国医院产品总经理。Knight女士于2019年从美敦力 PLC(美敦力)加入百特,2016年至2019年担任全球妇科健康、结直肠健康和疝气业务的副总裁/总经理。她在制药和医疗器械行业拥有近30年的经验,担任越来越多的职责。在加入美敦力之前,她曾在Kendal Healthcare、Tyco Healthcare和Covidien担任关键商业领导职务。Knight女士是Chanell MedSystems的董事会成员,该公司是一家医疗设备公司,致力于让每一位女性都能掌控自己的健康之旅,过上最好的生活,而TechNovation是一家全球科技教育非营利组织,旨在激励女孩成为生活和社区中的领导者和问题解决者。她此前担任Titan Medical Inc.董事会成员。


Heather Knight,is Executive Vice President and Group President, Medical Products & Therapies. She was appointed to her role leading Medical Products & Therapies in 2023 after serving as President, Acute Therapies, Clinical Nutrition, Medication Delivery, Latin America and Canada since 2021. She previously served as General Manager, U.S. Hospital Products from 2019 to 2021. Ms. Knight joined Baxter in 2019 from Medtronic plc (Medtronic), where she served as Vice President/General Manager of the global gynecologic health, colorectal health and hernia businesses from 2016 to 2019. She has nearly 30 years of experience across the pharmaceutical and medical device industries in roles of increasing responsibility. Prior to joining Medtronic, she held key commercial leadership positions at Kendal Healthcare, Tyco Healthcare, and Covidien. Ms. Knight is a member of the Board of Chanell Medsystems, a medical device company dedicated to empowering every woman to take control of her health journey and live her best life, and Technovation, a global technology education nonprofit that inspires girls to be leaders and problem solvers in their lives and their community. She previously served as a member of the Board of Titan Medical Inc.
Heather Knight是医疗产品和疗法执行副总裁兼集团总裁。自2021年起担任拉丁美洲和加拿大急性疗法、临床营养、药物输送、总裁后,她于2023年被任命为领导医疗产品和疗法的职务。她此前曾于2019年至2021年担任美国医院产品总经理。Knight女士于2019年从美敦力 PLC(美敦力)加入百特,2016年至2019年担任全球妇科健康、结直肠健康和疝气业务的副总裁/总经理。她在制药和医疗器械行业拥有近30年的经验,担任越来越多的职责。在加入美敦力之前,她曾在Kendal Healthcare、Tyco Healthcare和Covidien担任关键商业领导职务。Knight女士是Chanell MedSystems的董事会成员,该公司是一家医疗设备公司,致力于让每一位女性都能掌控自己的健康之旅,过上最好的生活,而TechNovation是一家全球科技教育非营利组织,旨在激励女孩成为生活和社区中的领导者和问题解决者。她此前担任Titan Medical Inc.董事会成员。
Heather Knight,is Executive Vice President and Group President, Medical Products & Therapies. She was appointed to her role leading Medical Products & Therapies in 2023 after serving as President, Acute Therapies, Clinical Nutrition, Medication Delivery, Latin America and Canada since 2021. She previously served as General Manager, U.S. Hospital Products from 2019 to 2021. Ms. Knight joined Baxter in 2019 from Medtronic plc (Medtronic), where she served as Vice President/General Manager of the global gynecologic health, colorectal health and hernia businesses from 2016 to 2019. She has nearly 30 years of experience across the pharmaceutical and medical device industries in roles of increasing responsibility. Prior to joining Medtronic, she held key commercial leadership positions at Kendal Healthcare, Tyco Healthcare, and Covidien. Ms. Knight is a member of the Board of Chanell Medsystems, a medical device company dedicated to empowering every woman to take control of her health journey and live her best life, and Technovation, a global technology education nonprofit that inspires girls to be leaders and problem solvers in their lives and their community. She previously served as a member of the Board of Titan Medical Inc.
Reazur Rasul

Reazur Rasul是医疗保健系统与技术执行副总裁兼集团总裁。自2022年起担任前线护理总裁后,他于2023年被任命为现职。在此之前,Rasul先生曾于2021年至2022年担任急性疗法和给药业务总经理,并于2017年至2021年担任急性疗法业务总经理。在2017年加入Baxter之前,他曾在惠普企业 Enterprise工作,担任副总裁兼全球云基础设施业务总经理。此前,他曾在GE Healthcare工作,在那里他担任过几个在业务领导和战略方面日益增加的职责,包括全球介入心脏病学业务总经理。Rasul先生的职业生涯始于Toyota Motor Corporation,最终在战略、产品开发和运营方面担任多个领导职务。


Reazur Rasul,is Executive Vice President and Group President, Healthcare Systems & Technologies. He was appointed to his current role in 2023 after serving as President of Front Line Care since 2022. Prior to that, Mr.Rasul served as General Manager for the Acute Therapies & Medication Delivery businesses from 2021 to 2022, and General Manager, for the Acute Therapies business from 2017 to 2021. Before joining Baxter in 2017, he worked with Hewlett Packard Enterprise where he was Vice President and General Manager of the Global Cloud infrastructure business. Previously, he worked with GE Healthcare where he held several roles of increasing responsibility in business leadership and strategy, including General Manager of the Global Interventional Cardiology business. Mr. Rasul began his professional career with Toyota Motor Corporation and ultimately held multiple leadership positions in strategy, product development and operations.
Reazur Rasul是医疗保健系统与技术执行副总裁兼集团总裁。自2022年起担任前线护理总裁后,他于2023年被任命为现职。在此之前,Rasul先生曾于2021年至2022年担任急性疗法和给药业务总经理,并于2017年至2021年担任急性疗法业务总经理。在2017年加入Baxter之前,他曾在惠普企业 Enterprise工作,担任副总裁兼全球云基础设施业务总经理。此前,他曾在GE Healthcare工作,在那里他担任过几个在业务领导和战略方面日益增加的职责,包括全球介入心脏病学业务总经理。Rasul先生的职业生涯始于Toyota Motor Corporation,最终在战略、产品开发和运营方面担任多个领导职务。
Reazur Rasul,is Executive Vice President and Group President, Healthcare Systems & Technologies. He was appointed to his current role in 2023 after serving as President of Front Line Care since 2022. Prior to that, Mr.Rasul served as General Manager for the Acute Therapies & Medication Delivery businesses from 2021 to 2022, and General Manager, for the Acute Therapies business from 2017 to 2021. Before joining Baxter in 2017, he worked with Hewlett Packard Enterprise where he was Vice President and General Manager of the Global Cloud infrastructure business. Previously, he worked with GE Healthcare where he held several roles of increasing responsibility in business leadership and strategy, including General Manager of the Global Interventional Cardiology business. Mr. Rasul began his professional career with Toyota Motor Corporation and ultimately held multiple leadership positions in strategy, product development and operations.
Alok Sonig

Alok Sonig,执行副总裁兼集团总裁,药品部。自2022年起担任总裁后,他于2023年被任命担任新职务。Sonig先生于2022年从Lupin,Inc.(卢平)加入百特,2018年至2022年担任美国首席执行官兼研发和生物仿制药全球主管。他带来了超过25年的生命科学行业经验。在加入Lupin之前,Sonig先生曾在Reddy博士实验室担任发达市场(美国、加拿大、欧洲和日本)的首席执行官。他还在百时美施贵宝工作了超过15年,在那里他担任过几个职位,在一般管理、全球战略和营销方面的责任越来越大。Sonig先生目前是美国大学、Kogod商学院和Sentry Sciences,Inc.的顾问委员会成员,并且是南亚制药理事会的董事会成员。


Alok Sonig,is Executive Vice President and Group President, Pharmaceuticals. He was appointed to his new role in 2023 after serving as President since 2022. Mr. Sonig joined Baxter in 2022 from Lupin, Inc. (Lupin), where he served as U.S. CEO and Global Head of R&D and Biosimilars from 2018 to 2022.Prior to Lupin, Mr. Sonig served as CEO of Developed Markets (U.S., Canada, Europe, and Japan) at Dr. Reddy's Laboratories. He also spent more than 15 years at Bristol Myers Squibb, where he held several positions of increasing responsibility in general management, global strategy and marketing. Mr. Sonig is currently a member of the Advisory Boards for the American University, Kogod School of Business, and Sentry Sciences, Inc., and is a member of the Board of the Southern Asian Pharmaceutical Council.
Alok Sonig,执行副总裁兼集团总裁,药品部。自2022年起担任总裁后,他于2023年被任命担任新职务。Sonig先生于2022年从Lupin,Inc.(卢平)加入百特,2018年至2022年担任美国首席执行官兼研发和生物仿制药全球主管。他带来了超过25年的生命科学行业经验。在加入Lupin之前,Sonig先生曾在Reddy博士实验室担任发达市场(美国、加拿大、欧洲和日本)的首席执行官。他还在百时美施贵宝工作了超过15年,在那里他担任过几个职位,在一般管理、全球战略和营销方面的责任越来越大。Sonig先生目前是美国大学、Kogod商学院和Sentry Sciences,Inc.的顾问委员会成员,并且是南亚制药理事会的董事会成员。
Alok Sonig,is Executive Vice President and Group President, Pharmaceuticals. He was appointed to his new role in 2023 after serving as President since 2022. Mr. Sonig joined Baxter in 2022 from Lupin, Inc. (Lupin), where he served as U.S. CEO and Global Head of R&D and Biosimilars from 2018 to 2022.Prior to Lupin, Mr. Sonig served as CEO of Developed Markets (U.S., Canada, Europe, and Japan) at Dr. Reddy's Laboratories. He also spent more than 15 years at Bristol Myers Squibb, where he held several positions of increasing responsibility in general management, global strategy and marketing. Mr. Sonig is currently a member of the Advisory Boards for the American University, Kogod School of Business, and Sentry Sciences, Inc., and is a member of the Board of the Southern Asian Pharmaceutical Council.
Jeanne K. Mason

Jeanne K. Mason于2006年从通用电气保险解决方案公司(GE Insurance Solutions)加入巴克斯特,这是一家主要的保险和再保险业务,负责全球人力资源职能。1988年,梅森女士在华盛顿特区的美国总会计师事务所(U.S.General Accounting Office)任职后,开始了在通用电气(General Electric GE)的职业生涯。她的通用电气经验包括在欧洲担任通用电气信息服务公司(GE Information Services)和通用电气金融房地产公司(GE Capital Real Estate)的领导职务。她是莱克县家庭服务董事会成员,也是全国非裔美国人人力资源协会芝加哥分会执行咨询委员会成员。


Jeanne K. Mason,is Executive Vice President and Chief Human Resources Officer having served in that capacity since 2006. Ms. Mason joined Baxter in 2006 from GE Insurance Solutions, a primary insurance and reinsurance business, where she was responsible for global human resource functions. Ms. Mason began her career with General Electric (GE) in 1988 after serving with the U.S. General Accounting Office in Washington, D.C. Her GE experience included leadership roles in Europe for GE Information Services and GE Capital Real Estate. She is a member of the Board of Directors of Family Service of Lake County and is a member of the Executive Advisory Council for the Chicago Chapter of National Association of African Americans in Human Resources.
Jeanne K. Mason于2006年从通用电气保险解决方案公司(GE Insurance Solutions)加入巴克斯特,这是一家主要的保险和再保险业务,负责全球人力资源职能。1988年,梅森女士在华盛顿特区的美国总会计师事务所(U.S.General Accounting Office)任职后,开始了在通用电气(General Electric GE)的职业生涯。她的通用电气经验包括在欧洲担任通用电气信息服务公司(GE Information Services)和通用电气金融房地产公司(GE Capital Real Estate)的领导职务。她是莱克县家庭服务董事会成员,也是全国非裔美国人人力资源协会芝加哥分会执行咨询委员会成员。
Jeanne K. Mason,is Executive Vice President and Chief Human Resources Officer having served in that capacity since 2006. Ms. Mason joined Baxter in 2006 from GE Insurance Solutions, a primary insurance and reinsurance business, where she was responsible for global human resource functions. Ms. Mason began her career with General Electric (GE) in 1988 after serving with the U.S. General Accounting Office in Washington, D.C. Her GE experience included leadership roles in Europe for GE Information Services and GE Capital Real Estate. She is a member of the Board of Directors of Family Service of Lake County and is a member of the Executive Advisory Council for the Chicago Chapter of National Association of African Americans in Human Resources.